​

Cadrenal Therapeutics Stock (NASDAQ:CVKD)

OwnershipFinancialsChart
Cadrenal Therapeutics by TradingView

Previous Close

$4.19

52W Range

$4.14 - $15.99

50D Avg

$5.24

200D Avg

$8.96

Market Cap

$12.36M

Avg Vol (3M)

$54.85K

Beta

1.61

Div Yield

-

CVKD Company Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jan 20, 2023

Website

CVKD Performance

CVKD Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-13.46M$-10.96M$-7.63M
Net Income-$-10.65M$-8.36M
EBITDA$-13.46M$-10.65M$-8.34M
Basic EPS$-6.64$-8.73$-9.63
Diluted EPS$-6.64$-8.73$-9.63

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
XCURExicure, Inc.
IBIOiBio, Inc.
TAOXTAO Synergies Inc.
RLYBRallybio Corporation
KLTOKlotho Neurosciences, Inc.
CLGNCollPlant Biotechnologies Ltd.
NRSNNeuroSense Therapeutics Ltd.
SONNSonnet BioTherapeutics Holdings, Inc.
ITRMIterum Therapeutics plc